Does empagliflozin pretreatment or BOHB infusion reduce ischemia reperfusion injury and infarct size during acute myocardial infarction?
Empagliflozin pretreatment and BOHB infusion provide cardioprotection during acute myocardial infarction by reducing infarct size and preserving systolic function, suggesting ketone body availability as a mechanism of SGLT2 inhibitor benefit.
One-week pretreatment with empagliflozin ameliorates ischemia reperfusion injury, reduces MI size and microvascular obstruction, increases myocardial salvage, preserves left ventricle systolic function, and lowers apoptosis and oxidative stress. Periprocedural intravenous infusion of BOHB during myocardial ischemia also induces cardioprotection, suggesting a role for BOHB availability as an additional mechanism within the wide spectrum of actions of SGLT2i.
Santos‐Gallego et al. (Sat,) studied this question.